Skip to main content
SpringerLink
Log in

NF2-Related Tumors and Malignant Peripheral Nerve Sheath Tumors

  • Chapter
  • First Online:
Adult CNS Radiation Oncology

Abstract

Neurofibromatosis (NF) types 1 and 2 are classified as phacomatoses with an autosomal-dominant inheritance pattern. They are important in the field of neuro-oncology as they predispose affected patients to a number of CNS tumors including acoustic schwannoma, meningioma, glioma, ependymoma, and malignant peripheral nerve sheath tumor (MPNST). Management of tumors in patients with NF can differ from that in the non-NF population owing to a natural history that may be more aggressive, a greater need to preserve function in patients with acoustic schwannoma, and the concern for increased risk of radiation-induced tumors in this population. The management of NF-related acoustic schwannoma, meningioma, and MPNST is discussed here, while management of glioma and ependymoma is presented in separate chapters.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373(9679):1974–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wishart JH. Case of tumours in the skull, dura mater and brain. Edinburgh Med Surg J. 1822;18:393–7.

    Google Scholar 

  3. Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329(6136):246–8.

    Article  CAS  PubMed  Google Scholar 

  4. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987;49(5):589–94.

    Article  CAS  PubMed  Google Scholar 

  5. Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93–7.

    Article  PubMed  Google Scholar 

  6. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29(12):841–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Evans DG, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35(6):450–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59(3):529–39.

    PubMed  PubMed Central  CAS  Google Scholar 

  9. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19(1):5–12.

    Article  CAS  PubMed  Google Scholar 

  10. Brackmann DE, Fayad JN, Slattery WH 3rd, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery. 2001;49(2):274–80. discussion 80–3

    PubMed  CAS  Google Scholar 

  11. Khrais T, Romano G, Sanna M. Nerve origin of vestibular schwannoma: a prospective study. J Laryngol Otol. 2008;122(2):128–31.

    Article  CAS  PubMed  Google Scholar 

  12. Slattery WH 3rd, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19(5):638–43.

    PubMed  Google Scholar 

  13. Jaaskelainen J, Paetau A, Pyykko I, et al. Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg. 1994;80(3):541–7.

    Article  CAS  PubMed  Google Scholar 

  14. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg. 2002;96(2):217–22.

    Article  PubMed  Google Scholar 

  15. Slattery WH 3rd, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 2004;25(5):811–7.

    Article  PubMed  Google Scholar 

  16. Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109–17.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Fisher LM, Doherty JK, Lev MH, et al. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol. 2009;30(6):835–41.

    Article  PubMed  Google Scholar 

  18. Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol. 2004;25(2):150–4.

    Article  PubMed  Google Scholar 

  19. Plotkin SR, Merker VL, Muzikansky A, et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014;35(1):e50–6.

    Article  PubMed  Google Scholar 

  20. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046–52.

    Article  PubMed  Google Scholar 

  21. Ruggieri M, Pratico AD, Evans DG. Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms. Semin Pediatr Neurol. 2015;22(4):240–58.

    Article  PubMed  Google Scholar 

  22. Kida Y, Kobayashi T, Tanaka T, et al. Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol. 2000;53(4):383–9. discussion 9–90

    Article  CAS  PubMed  Google Scholar 

  23. Linskey ME, Lunsford LD, Flickinger JC. Tumor control after stereotactic radiosurgery in neurofibromatosis patients with bilateral acoustic tumors. Neurosurgery. 1992;31(5):829–38. discussion 38–9

    Article  CAS  PubMed  Google Scholar 

  24. Mallory GW, Pollock BE, Foote RL, et al. Neurosurgery. 2014;74(3):292–300. discussion −1

    Article  PubMed  Google Scholar 

  25. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery. 2007;60(3):460–8. discussion 8–70

    Article  PubMed  Google Scholar 

  26. Roche PH, Regis J, Pellet W, et al. Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas. Neurochirurgie. 2000;46(4):339–53. discussion 54

    PubMed  CAS  Google Scholar 

  27. Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1288–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Subach BR, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2. J Neurosurg. 1999;90(5):815–22.

    Article  CAS  PubMed  Google Scholar 

  29. Bush DA, McAllister CJ, Loredo LN, et al. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery. 2002;50(2):270–3. discussion 3–5

    PubMed  Google Scholar 

  30. Harsh GR, Thornton AF, Chapman PH, et al. Proton beam stereotactic radiosurgery of vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2002;54(1):35–44.

    Article  PubMed  Google Scholar 

  31. Vernimmen FJ, Mohamed Z, Slabbert JP, et al. Long-term results of stereotactic proton beam radiotherapy for acoustic neuromas. Radiother Oncol. 2009;90(2):208–12.

    Article  PubMed  Google Scholar 

  32. Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery. 2003;53(3):577–86. discussion 86–8

    Article  PubMed  Google Scholar 

  33. Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg. 2005;102(Suppl):195–9.

    Article  PubMed  Google Scholar 

  34. Bari ME, Forster DM, Kemeny AA, et al. Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg. 2002;16(3):284–9.

    Article  CAS  PubMed  Google Scholar 

  35. Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000;82(4):998.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Noren G. Long-term complications following gamma knife radiosurgery of vestibular schwannomas. Stereotact Funct Neurosurg. 1998;70(Suppl 1):65–73.

    Article  PubMed  Google Scholar 

  37. Thomsen J, Mirz F, Wetke R, et al. Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol. 2000;21(3):364–70.

    Article  CAS  PubMed  Google Scholar 

  38. Comey CH, McLaughlin MR, Jho HD, et al. Death from a malignant cerebellopontine angle triton tumor despite stereotactic radiosurgery. Case report. J Neurosurg. 1998;89(4):653–8.

    Article  CAS  PubMed  Google Scholar 

  39. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603–18.

    PubMed  CAS  Google Scholar 

  40. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38(5):880–5. discussion 5–6

    Article  CAS  PubMed  Google Scholar 

  41. Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218(2):434–42.

    Article  CAS  PubMed  Google Scholar 

  42. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001;60(10):994–1003.

    Article  CAS  PubMed  Google Scholar 

  43. Slattery WH. Neurofibromatosis type 2. Otolaryngol Clin N Am. 2015;48(3):443–60.

    Article  Google Scholar 

  44. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81(6):496–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ardern-Holmes S, Fisher G, North K. Neurofibromatosis type 2: presentation, major complications, and management, with a focus on the pediatric age group. J Child Neurol. 2017;32(1):9–22

    Google Scholar 

  46. Bosch MM, Wichmann WW, Boltshauser E, et al. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol. 2006;124(3):379–85.

    Article  PubMed  Google Scholar 

  47. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 2010;99(3):341–7.

    Article  PubMed  Google Scholar 

  48. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4):715–23.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37(12):897–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Roser F, Nakamura M, Martini-Thomas R, et al. The role of surgery in meningiomas involving the optic nerve sheath. Clin Neurol Neurosurg. 2006;108(5):470–6.

    Article  PubMed  Google Scholar 

  51. Santacroce A, Walier M, Regis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70(1):32–9. discussion 9

    Article  PubMed  Google Scholar 

  52. Kondziolka D, Madhok R, Lunsford LD, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009;111(3):458–63.

    Article  PubMed  Google Scholar 

  53. Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009;73(1):208–13.

    Article  PubMed  Google Scholar 

  54. Birckhead B, Sio TT, Pollock BE, et al. Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series. J Neuro-Oncol. 2016;130(3):553–60.

    Article  CAS  Google Scholar 

  55. Liu A, Kuhn EN, Lucas JT Jr, et al. Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2. J Neurosurg. 2015;122(3):536–42.

    Article  PubMed  Google Scholar 

  56. Huang JH, Zhang J, Zager EL. Diagnosis and treatment options for nerve sheath tumors. Expert Rev Neurother. 2005;5(4):515–23.

    Article  PubMed  Google Scholar 

  57. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer; 2016.

    Google Scholar 

  58. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. LaFemina J, Qin LX, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20(1):66–72.

    Article  PubMed  Google Scholar 

  60. Seferis C, Torrens M, Paraskevopoulou C, et al. Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg. 2014;121(Suppl):160–6.

    PubMed  Google Scholar 

  61. Byerly S, Chopra S, Nassif NA, et al. The role of margins in extremity soft tissue sarcoma. J Surg Oncol. 2016;113(3):333–8.

    Article  PubMed  Google Scholar 

  62. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paeditr Drugs. 2007;9:239–48.

    Article  Google Scholar 

  64. Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38(1):e19–25.

    Article  PubMed  Google Scholar 

  65. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.

    Article  CAS  PubMed  Google Scholar 

  66. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014–22.

    Article  PubMed  Google Scholar 

  67. Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neurooncology. 2013;15(2):135–47.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA

    Timothy D. Struve, Luke E. Pater & John Breneman

Authors
  1. Timothy D. Struve
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luke E. Pater
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Breneman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Breneman .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Keck School of Medicine of USC, Norris Cancer Hospital, Los Angeles, California, USA

    Eric L. Chang

  2. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA

    Paul D. Brown

  3. Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington, USA

    Simon S. Lo

  4. Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

    Arjun Sahgal

  5. Department of Radiation Oncology, Taussig Cancer Institute Cleveland Clinic, Cleveland, Ohio, USA

    John H. Suh

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Struve, T.D., Pater, L.E., Breneman, J. (2018). NF2-Related Tumors and Malignant Peripheral Nerve Sheath Tumors. In: Chang, E., Brown, P., Lo, S., Sahgal, A., Suh, J. (eds) Adult CNS Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42878-9_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42878-9_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42877-2

  • Online ISBN: 978-3-319-42878-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation